Viridian Therapeutics, Inc. (VRDN)
| Market Cap | 279.57M |
| Revenue (ttm) | 2.60M |
| Net Income (ttm) | -132.66M |
| Shares Out | 8.11M |
| EPS (ttm) | -24.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19,937 |
| Open | 16.50 |
| Previous Close | 16.69 |
| Day's Range | 15.96 - 16.50 |
| 52-Week Range | 7.09 - 25.67 |
| Beta | 1.09 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Nov 9, 2021 |
About VRDN
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in...
Financial Performance
In 2020, VRDN's revenue was $1.05 million, a decrease of -76.46% compared to the previous year's $4.46 million. Losses were -$110.72 million, 164.4% more than in 2019.
Financial StatementsNews
Viridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R antibody for the treatment...
- VRDN-001 program remains on track for key proof of concept clinical data in Thyroid Eye Disease patients in the second quarter of 2022 -
Viridian Therapeutics to Present Preclinical Data on VRDN-001 and VRDN-002 at the 90th Annual Meeting of the American...
WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but under...
Viridian Therapeutics Announces Closing of Public Offering of Shares of Common Stock and Preferred Stock and Exercise...
WALTHAM, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but under...
Why Are Viridian Therapeutics Shares Moving Higher On Tuesday?
Viridian Therapeutics Inc (NASDAQ: VRDN) has priced an underwritten public offering with approximately $85.0 million gross proceeds. Viridian will offer 6.18 million shares at $11.00 per share, and 23,...
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock and Preferred Stock
WALTHAM, Mass., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but under...
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but under...
Viridian Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
WALTHAM, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company advancing new treatments for patients suffering fr...
Viridian Therapeutics Appoints Kristian Humer as Chief Financial Officer and Chief Business Officer
BOULDER, Colo., July 26, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but unders...
Viridian Therapeutics Appoints Jennifer Moses, CPA to the Board of Directors and as Chair of the Audit Committee
BOULDER, Colo., July 15, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but unders...
Viridian Therapeutics to Participate in the JMP Securities Life Sciences Conference
BOULDER, Colo., June 10, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but unders...
Viridian Therapeutics to Participate in Upcoming Investor Conferences
BOULDER, Colo., May 14, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underse...
Viridian Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates
BOULDER, Colo., May 06, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underse...
Viridian Therapeutics Reports 2020 Financial Results and Provides Corporate Updates
BOULDER, Colo., March 25, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but under...
Earnings Preview: Viridian Therapeutics
Viridian Therapeutics (NASDAQ:VRDN) releases its next round of earnings this Thursday, March 25. Here is Benzinga's essential guide to Viridian Therapeutics's Q4 earnings report.
Will Viridian Therapeutics, Inc. (VRDN) Report Negative Earnings Next Week? What You Should Know
Viridian Therapeutics, Inc. (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viridian Therapeutics To Host Conference Call Discussing Fourth Quarter And Full Year 2020 Results And Corporate Update
BOULDER, Colo., March 09, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but under...
Will Viridian Therapeutics, Inc. (VRDN) Report Negative Q4 Earnings? What You Should Know
Viridian Therapeutics, Inc. (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viridian Therapeutics to Present at Three Upcoming Investor Conferences
BOULDER, Colo., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a development-stage biopharmaceutical company, today announced that Jonathan Violin, Ph.D., President and Ch...
miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including...
BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc. (“V...